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Abstract 
Lean body mass (LM), consisting mostly of skeletal muscle, plays an important role in mobility 
and metabolic function. In a previous large scale study we identified five loci associated with 
LM adjusted for fat mass in kilograms. Such an adjustment may reduce the power to identify 
genetic signals having an association with both lean mass and fat mass.  
To identify additional LM loci and to be able to determine the impact of different fat mass 
adjustments, we performed genome-wide association analyses for whole body LM (in 20 cohorts 
of European ancestry with n=38,292) measured using DXA or bioelectrical impedance analysis, 
adjusted for sex, age, age
2
 and height with or without different fat mass adjustments (Model 1 no 
adjustment for fat mass;  Model 2 adjustment for fat mass as a percent of body mass; Model 3 
adjustment for fat mass in kilograms). Seven SNPs in/near separate loci, including one novel LM 
locus (TNRC6B), were successfully replicated in 47,227 individuals from 27 cohorts. The lean 
mass increasing allele of the identified genetic variant in the TNRC6B locus was also robustly 
associated with increased hand grip strength. 
Based on the strengths of the associations in Model 1 vs Model 3 we divided the LM loci into 
those with an effect on both lean mass and fat mass in the same direction and refer to those as 
“sumo wrestler” loci (FTO and MC4R).  In contrast, those loci with an impact specifically on 
lean mass were termed “body builder” loci (VCAN and ADAMTSL3). When evaluated in existing 
available GWAS databases, LM increasing alleles of SNPs in sumo wrestler loci were associated 
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with an adverse metabolic profile while LM increasing alleles of SNPs in”body builder” loci 
were associated with metabolic protection.  
In conclusion, we identified one novel LM locus (TNRC6B); our results suggest that genetically 
determined increase in lean mass might exert either harmful or protective effects on metabolic 
traits, depending on its relation to fat mass.  
 
keywords:  body composition, skeletal muscle, body fat, meta-analysis of genome wide 
association studies, metabolic profile 
 
 
ABBREVIATIONS: 
BIA - bioelectrical impedance analysis 
BMD - bone mineral density  
DXA – Dual energy X-ray absorptiometry  
EQTL - expression quantitative trait loci  
FDR  - false discovery rate  
GWS - genome-wide significant 
KASP - KBioScience Allele-Specific Polymorphism SNP genotyping system 
LD - linkage disequilibrium 
LM - Lean body mass 
MAF - minor allele frequency 
Q-Q - quantile–quantile (plots) 
sGWS  - suggestive genome-wide significance  
 
 
 
27 
 
Introduction  
Lean body mass (LM), consisting mostly of skeletal muscle, plays an important role in mobility 
and metabolic function. It is well established that high fat mass results in insulin resistance, 
increased risk of Type 2 diabetes and dyslipidemia. Observational studies indicate that lean mass 
adjusted for weight or fat mass is inversely associated with insulin resistance and metabolic 
abnormalities.
[1]
 However, the causal effects of lean mass on metabolic traits are unclear. 
Adipocytes and myocytes share common mesenchymal ancestry
[2]
 and factors (genetic and/or 
environmental) stimulating the development of mesenchymal stem cells towards the myocyte 
lineage instead of the adipocyte lineage may lead to more favorable body composition.  
In a recent large scale study we identified five loci associated with LM adjusted for fat mass in 
kilograms.
[3]
  In that study we were primarily interested in genes contributing to lean mass 
independent of those regulating fat mass.
[3]
  Because lean mass is positively correlated with fat 
mass and may even be stimulated to increase by the mechanical demands of carrying more fat 
mass, our previous results adjusted for fat mass in the statistical models. A potential limitation of 
this strategy of adjusting for fat mass is that the ability to identify genetic signals with an impact 
on both lean and fat mass will be reduced. Nevertheless, the FTO signal was found to be 
significantly associated with lean mass after fat adjustment and the direction of this association 
was the same as the association with fat mass found in other studies.
[4]
  To be less restrictive in 
our quest to identify additional lean mass loci and to gain more insight into the lean-fat mass 
relationship and its health consequences, in this study we performed different statistical models 
with either no fat adjustment at all, or with one of two fat adjustment models: fat as a percentage 
of body mass, or fat in absolute kilograms. 
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For identified lean mass SNPs, we also aimed to evaluate the associations with a variety of 
musculoskeletal and metabolic traits. Finally, we aimed to explore if the associations with 
musculoskeletal and metabolic parameters differed for significant loci identified in models 
without fat mass adjustment compared with those having the strongest association in models 
with fat mass adjustment.  
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METHODS 
Study summary: We performed a genome-wide association study meta-analysis on whole body 
lean mass in a set of discovery cohorts (Stage I), then meta-analyzed the discovery SNPs in 
replication cohorts (Stage II), followed by a combined analysis with discovery and replication 
cohorts. The total sample size for the combined analysis was 85,519 individuals of European 
ancestry from 47 studies.  
 
Study Population  
 The Stage I Discovery sample comprised 38,292 individuals of European ancestry drawn 
from 20 cohorts with a variety of epidemiological designs and participant characteristics 
(Supplementary Table S1 and Supplementary Note 1). Whole body lean mass was measured 
using DXA (10 cohorts, n=21,074) and BIA (10 cohorts, n=17,218).  Of the 20 cohorts, 15 
consisted of males and females, while 2 had males and 3 had females only. In total, the cohorts 
included 22,705 women and 15,587 men.   
Twenty-nine additional studies were used for replication with a total sample size of 
47,227 subjects of European ancestry.  The Stage II, Replication included cohorts with either 
existing GWAS data that were unavailable at the time of the Stage I Discovery, or cohorts 
without GWAS data who agreed to undergo de novo genotyping.  Because some of the 
replication cohorts performed de novo genotyping, there were fewer data points for SNPs that 
were newly genotyped compared to SNPs that were imputed from already available GWAS 
studies.  All studies were approved by their institutional ethics review committees and all 
participants provided written informed consent. 
 
Lean Mass Measurements  
Lean mass was measured in all cohorts using either DXA or BIA.  DXA provides a three 
compartment body composition assessment based on specific x-ray attenuation properties: bone 
mineral, lipid (triglycerides, phospholipid membranes, etc.) and lipid-free soft tissue.  Each pixel 
on the DXA scan is quantitatively partitioned into these three tissue types.  For the cohorts with 
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DXA measures, the phenotype used for these analyses was the lipid-free, soft tissue 
compartment that is referred to as lean mass, and is the sum of body water, protein, glycerol and 
soft tissue mineral mass. Two lean mass phenotypes were used: whole body lean mass and 
appendicular lean mass.  The latter was obtained by DXA while considering only pixels in the 
arms and legs collectively, which has been demonstrated to be a valid measure of skeletal muscle 
mass.
[5]
  Some of the cohorts estimated body composition using BIA, which has been detailed in 
our previous work.
[3]
  For BIA cohorts with specific resistance and reactance measures, we used 
the validated equation from Kyle et al. with an R
2
 of 0.95 between BIA and DXA to calculate the 
appendicular lean mass.
[6]
 
 
STAGE 1:   GENOME-WIDE ASSOCIATION ANALYSES IN DISCOVERY COHORTS 
Genotyping and Imputation: Genome-wide genotyping was done in each study on a variety of 
platforms following standard manufacturer protocols.  Quality control was performed 
independently for each study.  To facilitate meta-analysis, each group performed genotype 
imputation with IMPUTE
[7]
 or MACH
[8]
 software using HapMap Phase II release 22 reference 
panels (CEU or CHB/JPT as appropriate). Overall imputation quality scores for each SNP were 
obtained from IMPUTE (“proper_info”) or MACH (“rsq_hat”). Details on the genotyping 
platform used, genotype quality control procedures and software for imputation employed for 
each study are presented in Supplementary Table S2. Because the project started prior to the 
creation of denser imputation panels, only Hap Map II based imputation was available. 
 
Study-specific genome-wide association analyses with lean mass and different lean mass models: 
Details about study-specific genome-wide association analyses and meta-analyses have been 
described previously.
[3]
 Briefly, in each study, a multiple linear regression model with additive 
genetic effect was applied to test for phenotype-genotype associations using ~2.0 to 2.5 million 
genotyped and/or imputed autosomal SNPs. Because lean mass is correlated with fat mass and 
height, we pre-specified three models of adjustment: model 1: adjustment for sex, age, age
2
, 
height; model 2: adjustment for sex, age, age
2
, height, percent fat mass; model 3: adjustment for 
sex, age, age
2
, height, fat mass in kilograms. Other covariates adjusted in the model included 
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ancestral genetic background using principal components and, when appropriate, study specific 
covariates such as clinical center for multi-center cohorts. For family-based cohorts, including 
the Framingham Study, ERF, UK-Twins, Old Order Amish Study and the Indiana cohort, 
familial relatedness was taken into account in the statistical analysis.
[3]
 
 
Meta-analyses: Meta-analyses were conducted using the METAL package 
(www.sph.umich.edu/csg/abecasis/metal/). We used the inverse variance weighting and fixed 
effect model approach.  Prior to meta-analysis, we filtered out SNPs with low minor allele 
frequency, MAF (< 1%) and poor imputation quality (proper_info < 0.4 for IMPUTE and 
rsq_hat < 0.3) and applied genomic control correction where the genomic control parameter 
lambda (λGC ) was > 1.0.   
We used quantile–quantile (Q-Q) plots of observed versus expected –log10 (p-value) to examine 
the genome wide distribution of p-values, Manhattan plots to report genome-wide p-
values, regional plots for genomic regions within 100Kb of top hits, and forest plots for meta-
analyses and study-specific results of the most significant SNP associations. For all three models, 
a threshold of p < 5 x 10
-8 
was pre-specified as being genome-wide significant (GWS), while a 
threshold of p < 2.3 x 10
-6
 was used to select SNPs for a replication study (suggestive genome-
wide significant – sGWS).   
 
STAGE 2:  REPLICATION  
In each GWS or sGWS locus, we selected the lead SNP with the lowest p-value for replication.  
In addition, GWS or sGWS SNPs that had low linkage disequilibrium (LD) with the lead SNPs 
(r
2
 < 0.5) were also selected for replication.  Both in-silico replication and de-novo genotyping 
for replication was conducted.  In-silico replication was done in 24 cohorts with GWAS SNP 
genotyping that did not have data available at the time of the initial discovery efforts 
(Supplementary Table S3).  De-novo replication genotyping was done using KBioScience Allele-
Specific Polymorphism (KASP) SNP genotyping system (in OPRA, PEAK25, AGES, CAIFOS, 
DOPS cohorts), TaqMan (METSIM), Illumina OmniExpress + Illumina Metabochip (PIVUS 
and ULSAM), or Sequenom's iPLEX (WHI) (Supplementary Table S4). Samples and SNPs that 
did not meet the quality control criteria defined by each individual study were excluded. 
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Minimum genotyping quality control criteria were defined as: SNP call rate > 90% and Hardy-
Weinberg equilibrium p > 1x10
-4
.    
 
META-ANALYSIS OF REPLICATION AND DISCOVERY STUDIES 
In the replication stage, we meta-analyzed results from individuals of European descent only. A 
successful replication was considered if the association p-value in the cumulative-meta-analysis 
was GWS and less than the discovery meta-analysis p-value. Using the METAL package we also 
estimated I
2
 to quantify heterogeneity and p-values to assess statistical significance for a total of 
12 associations (three SNPs from model 1, four from model 2 and five from model 3) that were 
replicated in the cumulative-meta-analysis. Appendicular lean mass was available in a subsample 
of those with whole body lean mass (n=70,690 from 38 studies) and models 1-3 for appendicular 
lean mass were evaluated for the replicated GWS associations from the whole body lean mass 
analyses. 
 
ANNOTATION AND ENRICHMENT ANALYSIS OF REGULATORY ELEMENTS   
We predicted the function of coding variants by PolyPhen-2. For all replicated variants, we 
annotated potential regulatory functions based on experimental epigenetic evidence including 
DNase hypersensitive sites, histone modifications, and transcription factor binding sites in 
human cell lines and tissues from the ENCODE Project and the Epigenetic Roadmap Project. We 
first selected SNPs in high LD (r
2
 ≥ 0.8) with GWAS lead SNPs based on the approach of 
Trynka, et al.
[9]
 We then identified potential enhancers and promoters in the GWAS loci (GWAS 
SNPs and SNPs in LD with the GWAS SNPs) across 127 healthy human tissues/normal cell 
lines available in the ENCODE Project and the Epigenetic Roadmap Project from the HaploReg4 
web browser
[10]
 predicted by ChromHMM.
[11]
 To evaluate if replicated GWAS loci were 
enriched with regulatory elements in skeletal muscle tissue, we performed a hypergeometric test. 
Specifically we tested whether estimated tissue-specific promoters and enhancers in a GWAS 
locus were enriched in 8 relevant skeletal muscle tissues/cell lines vs. enrichment in non-skeletal 
muscle tissues (119 tissues/cell lines). The permutation with minimum p-value approach was 
performed to correct for multiple testing. Permutation p-values < 0.05 were considered 
statistically significant. In addition, we also performed enrichment analyses in smooth muscle 
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tissues/cells, fat tissue, brain, blood cells and gastrointestinal tract tissues. The 8 skeletal muscle 
relevant tissues/cells were excluded when conducting enrichment analyses for other tissue types. 
The detailed information for tissue types and chromatin state estimation is described in the 
Supplementary Materials (Suppl. Note 2). 
     
CIS-EXPRESSION QUANTITATIVE TRAIT LOCI (EQTL)  
We looked up cis-eQTL information from GTEx data on the 7 replicated GWS loci, 
SNPs rs2943656, rs9991501, rs2287926, rs4842924, rs9936385, rs10871777 and rs 733381 with 
gene expression within 2Mb of the SNP position. Multiple testing was corrected by using false 
discovery rate (FDR q value < 0.05) to account for all pairs of SNP-gene expression analyses in 
multiple tissues. 
 
Look-ups of replicated SNPs in GWAS of metabolic and musculoskeletal traits 
For the seven replicated lean mass SNPs, we performed look-ups of relevant metabolic and 
musculoskeletal traits using available results from published GWAS meta-analyses. The 
metabolic and musculoskeletal traits evaluated included  percent fat 
[12]
, BMI 
[4]
, coronary artery 
disease 
[13]
, type 2 diabetes 
[14]
, HOMA insulin resistance 
[15]
, triglycerides 
[16]
, total cholesterol 
[16]
, LDL cholesterol 
[16]
, HDL cholesterol 
[16]
, hand grip strength [17, 18], bone mineral density 
(BMD)
[19]
 and fractures (manuscript). (CITE ABSTRACT OF FX GWAS OR TIMING MIGHT 
BE OK FOR THE FRACTURE PAPER TO BE ACCEPTED AT BMJ)  We will keep this in the 
paper but revisit according to how the timing works out and if other fx paper authors are ok with 
this.)  
 
Genetic correlation in LD score regression 
We applied LD score regression to estimate genetic correlations across several muscle-related 
traits from summary-level data of publicly available GWAS. We used LD Hub
[20]
,  which is a 
centralized database of summary-level GWAS results for hundreds of diseases/traits from 
multiple consortia and online resources, as well as a web interface that automates the LD score 
regression analysis pipeline 
[21]
. According to Bulik-Sullivan, et al. 
[22]
, the genetic correlation for 
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a set of SNPs S is calculated as rS (y1 ,y2 ):=ρ S (y1 ,y2 ) /                     , where ρS  is 
genetic covariance among SNPs in S, y1 and y2 denote phenotypes, and h 
2
S, the heritability 
explained by SNPs in S.  
 
  
 
 
35 
 
 
Results 
 
GWAS META-ANALYSES FOR DISCOVERY AND REPLICATION  
Descriptions and characteristics of the study populations in the discovery stage and the 
replication stage are shown in Supplementary Table S1, S5, and Supplementary note 1. The age 
of the participants ranged from 18 to 100 years. In the GWAS discovery set, comprising 38,292 
participants for whole body lean mass, a substantial excess of low p-values compared to the null 
distribution was observed after genomic control adjustment of the individual studies prior to 
meta-analysis: λGC = 1.078 λGC =1.075and  λGC =1.076, for Model 1 (not adjusted for fat masss), 
Model 2 (adjusted for fat %) and Model 3 (adjusted for fat mass in kg), respectively (Figure S1A-
C).  
Tables 1A-C show the genome-wide significant (GWS) and suggestive (sGWS) results for the 
three models in the discovery set (see also Fig. S2. In Model 1, we observed three independent 
GWS results (in/near FTO, MC4R and CALCR) and four sGWS results (in/near HSD17B11, 
GMPPA, CMTM8 and C10orf39; Table 1A; Fig S2A). In Model 2, we observed three 
independent GWS results (in/near HSD17B11, FTO and CALCR) and 10 sGWS results (in/near 
MC4R, TNRC6B, RHOC, GMPPA, NUDT3, AKR1B1, ANGPT2, ZBTB16, ADAMTSL3, SMG6; 
Table 1B; Fig S2B). 
Data for Model 3 have already been presented in a previous publication
[3]
 but for comparison we 
display it in Table 1C.  To reiterate, in Model 3, we observed one independent GWS result 
in/near HSD17B11 and 10 sGWS results (in/near IRS1, VCAN, ADAMTSL3, FTO, RHOC, 
PRR16, FRK, AKR1B1, CALCR, KLF12; Table 1C; Fig S2C). 
We selected all GWS and sGWS associations for all three models (Tables 1A, 1B, 1C) to 
conduct a replication study in a set of 27 cohorts comprising up to 47,227 participants of 
European descent. Due to limited resources, five of the sGWS signals were evaluated only in the 
cohorts available for in-silico replication (Tables 1A, 1B, 1C).  
 
 
36 
 
The upper parts of each panel in Tables 1A-C show the results for successfully replicated SNPs 
(defined as combined p-value <5x10
-8
 and lower than discovery P-values) in participants, who 
were part of the discovery phase, replication phase, and the combined results. For Model 1, 
combined analysis of the discovery and replication cohorts successfully replicated 3 SNPs 
in/near HSD17B11, FTO and MC4R (P-values between 1.6x10
-8
 and 1.8 x 10
-30
). For Model 2, 
the same 3 SNPs as reported for Model 1 were successfully replicated and in addition one SNP 
in/near TNRC6B was also successfully replicated (P-values between 7.3x10
-10
 and 2.4 x 10
-20
). 
For Model 3, combined analysis of the discovery and replication cohorts successfully replicated 
5 SNPs in/near IRS1, HSD17B11, VCAN, ADAMTSL3 and FTO (P-values between 1.4x10
-8
 and 
1.5 x 10
-11
;  Results of Model 3 SNPs have been previously reported 
[3]
 but are shown here for 
comparison (Table 1C).  
None of the 12 replicated associations (three for Model 1, four for model 2 and five for model 3) 
had significant heterogeneity at α=0.0042 (0.05/12, Bonferroni corrected for 12 tests). Only mild 
heterogeneity was indicated for the SNP in/near FTO in all three models (Model 1, I
2
=38%,; 
Model 2, I
2
=33%; Model 3, I
2
=33%; Tables 1A, 1B, 1C). 
In total 7 SNPs in independent loci (in/near IRS1, HSD17B11, VCAN, ADAMTSL3, FTO, MC4R 
and TNRC6B) were sucessfully replicated in any of the three models and the results for these 7 
SNPs in the three different models for whole body lean mass are given in Table 2. The seven 
SNPs were nominally (p<0.05) significant in all three models except for the SNP in/near IRS1, 
which was not associated with lean mass unadjusted for fat mass in model 1. Very similar 
associations were observed when these 7 SNPs were evaluated for their associations with 
appendicular lean mass available in up to 70,690 subjects of European descent (Suppl. Table S6).    
 
The impact of fat mass adjustment for lean mass loci - “sumo wrestler loci and body builder 
loci”  
In general the results from Model 1 and Model 3 differed most from each other while the 
associations for Model 2 were intermediate. Therefore, in the studies evaluating the impact of fat 
mass adjustment for lean mass loci, we mainly compared the results between Model 1 and Model 
3. Six of the seven loci (FTO, MC4R, TNRC6B, HSD17B11, VCAN and ADAMTSL3) had an 
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impact both on the absolute amount of lean mass (Model 1) and the amount of lean mass 
adjusted for fat mass (Model 3). However, the strengths of the associations in Model 1 vs Model 
3 varied substantially. The FTO and MC4R  signals had high Model 1/Model 3 ratios of Beta 
values for the association with lean mass (M1/M3 ratio 222-234%), demonstrating that the 
strengths of the associations were reduced after fat mass adjustment. This suggests that these two 
loci have an impact on both lean mass and fat mass in the same direction and this is also 
supported by the fact that they are associated with BMI and fat mass in the same direction as 
with lean mass (Table 3, Suppl. Table S7). As the alleles of the FTO and MC4R signals that were 
associated with greater lean mass also were associated with increased fat mass we named them 
“sumo wrestler” loci (Table 3; Suppl. Table S7).  
In contrast, there were two lean mass loci that had a low Model 1/Model 3 ratio of Beta values 
for the association with lean mass (M1/M3 ratio 64-67%), including the VCAN and ADAMTSL3 
loci. For these loci the lean mass associations were stronger after adjustment for fat mass. This 
means that these two loci have a substantial impact specifically on lean mass with associations in 
the opposite direction or no association with fat mass (Table 3, Suppl. Table S7). As the alleles 
of the VCAN and ADAMTSL3 loci that were associated with greater lean mass were associated 
with slightly reduced fat mass, we named them “body builder” loci. The TNRC6B and 
HSD17B11 loci had intermediate Model 1/Model 3 ratios of Beta values for the association with 
lean mass (M1/M3 ratio 120-125%), suggesting that their impact on lean mass did not appear to 
be influenced by fat mass, so we called them “intermediate” loci (Table 3; Suppl. Table S7). 
The signal in/near IRS1 was not associated with lean mass without adjustment for fat mass.  As 
shown in Tables 3 and S7, the lean mass increasing allele in/near IRS1 was associated with lower 
fat mass. This association with lower fat mass may indirectly make the association with fat mass 
adjusted lean mass to be significant in the opposite direction. It is indeed a locus with an impact 
on the ratio between lean and fat mass but with no significant association with the absolute 
amount of lean mass when the effect of fat mass is not taken into account. The lean mass 
increasing allele was associated with reduced BMI and fat mass (Table 3, Suppl. Table S7), 
suggesting that its inverse association with fat mass is dominant for its effect on BMI, which is 
influenced by both lean mass and fat mass. We, therefore, named the IRS locus a “fat-mediated 
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lean mass” locus as it primarily appears to impact the amount of fat mass (Table 3; Suppl. Table 
S7). 
 
Metabolic associations for lean mass increasing alleles  
We next evaluated the associations with metabolic traits for the seven replicated lean mass SNPs,  
using available results from GWAS-meta-analyses of these traits (Table 3; Suppl. Table S7). The 
lean mass increasing alleles of SNPs in/near the two sumo wrestler loci (FTO and MC4R) were 
in general associated with an adverse metabolic profile both regarding carbohydrate 
metabolism (higher fasting insulin, higher HOMA-IR and increased risk of diabetes mellitus) 
and lipid metabolism (higher serum triglycerides and lower HDL cholesterol; Table 3; Suppl. 
Table S7). In addition, the lean mass increasing allele of the SNP in/near FTO was associated 
with increased risk of coronary artery disease (Table 3). In contrast, the lean mass increasing 
alleles of the SNPs in the two body builder loci (VCAN and ADAMTSL3) were in general 
associated with some metabolic protection both regarding carbohydrate metabolism (lower 
fasting insulin or reduced risk of diabetes mellitus) and lipid metabolism (lower serum 
triglycerides or higher HDL cholesterol; Table 3 presents general direction of associations; 
Suppl. Table S7 actual beta coefficients). The lean mass signals in the intermediate lean mass 
loci (TNRC6B and HSD17B11), not influenced by fat mass adjustment, did not have any major 
impact on metabolic traits.  
As reported previously 
[23]
, the lean mass increasing allele of the SNP in the fat-mediated lean 
mass locus IRS1 was associated with an adverse metabolic profile (Table 3; Suppl. Table S7).  
 
Musculoskeletal associations of lean mass increasing alleles  
We also evaluated the associations between the seven replicated lean mass SNPs and 
musculoskeletal traits. Importantly, the lean mass increasing alleles of the SNPs in/near TNRC6B 
and in/near ADAMTSL3 were robustly associated with higher hand grip strength (Table 4, Table 
S8). In general the associations with the other musculoskeletal traits (Table 4 and Suppl. Table 
S8) were less pronounced compared with the associations with metabolic traits (Table 3 and 
Suppl. Table S7) and no general pattern for the signals in the sumo wrestler loci vs. the signals in 
the body builder loci was observed for the musculoskeletal traits (Table 4; Suppl. Table S8). 
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Surprisingly the lean mass increasing allele of the SNP in/near TNRC6B was associated with 
lower lumbar spine BMD and increased risk of fractures.  
 
Genetic correlations with lean mass by LD score regression  
We next determined the genetic correlations between lean mass phenotypes and a variety of 
parameters with a focus on metabolic and musculoskeletal phenotypes using LD score regression 
(Table 5).  Obesity traits, including both extreme phenotypes, such as childhood obesity and 
extreme BMI, and quantitative traits, such as BMI and waist-to-hip ratio, demonstrated strong 
positive genetic correlation with lean mass in the model not adjusted for fat mass (Model 1) and 
as expected these genetic correlations were attenuated after fat mass adjustment (Model 2 and 
Model 3; Table 5).  
For all carbohydrate metabolism related traits (type 2 diabetes mellitus, fasting glucose,  fasting 
insulin, fasting proinsulin, HbA1C and HOMA-IR) positive genetic correlations with lean mass 
in Model 1 were observed.  All these correlations were attenuated after fat mass adjustment in 
Models 2 and 3.  
When lipid metabolism related traits were evaluated in lean mass Model 1, a positive genetic 
correlation was observed for serum triglycerides and negative genetic correlations were observed 
for total cholesterol and HDL cholesterol (Table 5). The significant genetic correlation with 
triglycerides was lost in lean mass Model 3 adjusted for fat mass in kg. Although the genetic 
correlations with HDL cholesterol was attenuated after fat mass adjustment (Model 3), the 
correlation was still significant.   
There was a modest positive genetic correlation between BMD parameters and lean mass in all 
three models while the genetic correlation with grip strength, a proxy for muscle function, was 
observed in Model 3 but not in Model 1 (Table 5).   
Age at menarche and age at menopause can be regarded as indicators of lifetime sex steroid 
exposure. Age at menarche but not age at menopause displayed negative genetic correlations 
with lean mass in all three models although most pronounced in Model 1 (Table 5).  
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Annotation and enrichment analysis of regulatory elements 
In the enrichment analysis of tissue-specific regulatory elements using experimental epigenetic 
evidence (DNase hypersensitive sites, histone modifications, and transcription factor-binding 
sites in human cell lines and tissues from the ENCODE Project and the Epigenetic Roadmap 
Project), SNPs in the TNR6CB locus were significantly enriched in these regulatory elements in 
blood cells, but not in muscle or other selected tissues after multiple testing correction (Suppl. 
Table S9). There was no significant tissue specific enrichment of regulatory elements for the 
MC4R locus. The enrichment results for the other loci have previously been presented.
[3]
 
 
Expression quantitative trait loci 
No significant association was found between rs733381 and TNRC6B gene expression in the 
skeletal muscle tissue (p=0.13, N=491) fom GTEx data; although individuals with homozygosity 
of minor allele G appear to have relatively lower TNRC6B gene expression in the skeletal muscle 
tissue. We also looked at eQTLs of rs733381 in other tissues from GTEx data, but none of the 
associations achieved statistical significance after multiple testing correction. MC4R gene 
expression is not detectable in the skeletal muscle tissue, whole blood and many other tissue 
types, except for brain tissues, esophagus and testis from GTEx data. Among those tissues with 
detectable MC4R gene expression, the smallest p-value between rs10871777 and MC4R gene 
expression was found in the frontal cortex brain tissue (p=0.017, N=118). However, no statistical 
significance was found after multiple testing correction. The eQTL results for the other loci have 
previously been presented.
[3]
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Discussion 
Body weight consists of lean mass (LM), fat mass and bone mass, each with substantial heritable 
components and each playing important roles in physical function and metabolism. Since LM is 
correlated with fat mass, it is difficult to identify genetic determinants specific for LM. In 
addition, this makes it challenging to determine the metabolic health consequences of LM 
independent of fat mass. In the present study, we performed large scale GWAS for LM without 
or with different fat mass adjustments and we identified genetic variants in seven separate loci, 
including one novel locus (TNRC6B), associated with LM. Based on the relative strengths of the 
associations in models without and with fat adjustments we divided the LM loci that we 
identified into those with an effect on both LM and fat mass in the same direction (named sumo 
wrestler loci) and those with an impact specifically on LM (named body builder loci). LM 
increasing alleles of SNPs in Sumo wrestler loci were associated with an adverse metabolic 
profile while LM increasing alleles of SNPs in body builder loci were associated with metabolic 
protection.  
The 7 SNPs that were were reproducibly associated with LM in any of the three models used 
were in independent loci (in/near IRS1, HSD17B11, VCAN, ADAMTSL3, FTO, MC4R and 
TNRC6B). Five of these SNPs (in/near IRS1, HSD17B11, VCAN, ADAMTSL3 and FTO) were 
identified in the model adjusted for fat mass in kilograms and the results from this model have 
been previously reported
[3]
. However, in the present study, we could determine how the strengths 
of the LM associations for these five SNPs were affected in different models without or with fat 
mass adjustement, enabling us to divide them into Sumo wrestler loci or body builder loci.  
A genetic variant in the MC4R locus was in the present study GWS associated with LM in the 
model not adjusted for fat mass while the association was weaker in the model adjusted for fat 
mass in kilograms, and consequently this locus was categorized as a Sumo wrestler locus. The 
MC4R locus has not previously been identified as a LM locus in a GWAS on LM. However, in a 
GWAS on fat mass, the MC4R locus was found to be associated with not only fat mass but also 
in secondary analyses with LM in the same direction.
[24]
 These findings indicate that the MC4R 
locus has a pleiotropic effect, regulating both fat mass and lean mass in the same direction. 
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Importantly, the TNRC6B (Trinucleotide Repeat Containing 6B) locus was in the present study 
identified as a novel LM locus and comparison of the strengths of the associations in the 
different models of fat mass adjustments demonstrated that its LM association was only 
modestly affected by different fat mass adjustments. TNRC6B is a protein coding gene in 
pathways related to cellular senescence, innate or adaptive immune system, Wnt signaling, and 
calcium modulating pathways (GO:0007223). In addition to the LM, BMI, HDL, grip strength, 
LS-BMD, and fracture associations presented here, other GWAS have reported the TNRC6B 
locus GWS associated with a “chronotype” (defined as “Morningness” or “Eveningness”) 
phenotype
[25]
, uterine fibroids
[26]
, and mammographic density
[27]
. Understanding the mechanisms 
by which TNRC6B variants relate to body composition and this multitude of phenotypes may be 
useful for mitigating a wide range of aging and disease states. 
.  
The LM increasing allele of SNPs in the Sumo wrestler loci (FTO and MC4R) were associated 
with higher fasting insulin, higher HOMA-IR, increased risk of diabetes mellitus, higher serum 
triglycerides and lower HDL cholesterol. In addition, the LM increasing allele of the SNP in the 
FTO locus was associated with inceased risk of coronary artery disease. Thus, genetically 
determined increase in LM by genetic variants in Sumo wrestler loci is clearly associated with an 
adverse metabolic profile. In contrast, the LM increasing alleles of SNPs in the body builder loci 
(VCAN and ADAMTSL3) were in general associated with a beneficial metabolic profile both 
regarding carbohydrate metabolism (lower fasting insulin or reduced risk of diabetes mellitus) 
and lipid metabolism lipid metabolism (lower serum triglycerides or higher HDL cholesterol). 
The intermediate loci (TNRC6B and HSD17B11) were not associated with a clear metabolic 
profile. These findings suggest that a genetically determined higher LM per se without affecting 
fat mass has favorable metabolic effects while a genetically determined higher LM that is 
associated with a higher fat mass as well has adverse metabolic consequences. Alternatively the 
described associations with metabolic traits could be explained by pleiotropic effects of the 
respective genes. 
 
While we could divide the SNPs that we found associated with LM in the different models into 
categories based on a relation with LM and fat mass or LM only, we found that the SNP in IRS1 
behaved differently from the other genes. The LM increasing allele in/near IRS1 was associated 
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with lower fat mass and lower BMI but had no significant effect on the absolute amount of LM 
when the effect on fat mass was not taken into account. We, therefore, named the IRS locus a 
“fat-mediated lean mass” locus as it primarily appears to impact the amount of fat mass. 
Besides cross-phenotype analyses, we determined the genetic correlations between LM 
phenotypes and a variety of parameters with a focus on metabolic and musculoskeletal 
phenotypes using LD score regression. Genetic correlation in LD score regression is 
(asymptotically) proportional to Mendelian randomization estimates
[22]
. This method has an 
advantage for several reasons: it does not require individual genotypes, is not restricted to 
genome-wide significant SNPs, and there is no need for LD-pruning (which loses information if 
causal SNPs are in LD)
[22]
. LD score regression analyses revealed strong positive genetic 
correlations between LM and several obesity traits and carbohydrate metabolism related traits 
such as type 2 diabetes mellitus, fasting glucose and fasting proinsulin. These genetic 
correlations were attenuated in models adjusted for fat mass in kilograms, supporting the notion 
that genes that determine both fat mass and LM have a stronger genetic overlap with genes that 
determine obesity and glucose intolerance than genes that determine LM irrespective of fat mass. 
Similar obeservations with stronger genetic correlations in models not adjusted for fat mass were 
made for the positive genetic correlations with serum triglycerides and the negative genetic 
correlations with HDL cholesterol.  
 
Cross-phenotype analyses revealed that the LM increasing alleles of the SNPs in/near TNRC6B 
and in/near ADAMTSL3 were robustly associated with higher hand grip strength, suggesting that 
increased muscle mass resulted in increased muscle strength. This notion is supported by our 
finding of a positive genetic correlations between LM and grip strength in models adjusted for 
fat mass. In general, fat mass adjustment attenuated the genetic correlations between LM and 
metabolic traits, whereas the same adjustment enhanced or did not change the genetic 
correlations between LM and musculoskeletal traits. 
 
Interestingly, age at menarche but not age at menopause displayed negative genetic correlations 
with LM in all three models but was most pronounced in Model 1, implying that genes related to 
both fat mass and LM are correlated with genes determining age at menarche. One may speculate 
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that the amount of LM is involved in the onset of menarche. Alternatively it is possible that 
augmented sex hormone status might be the link between early menarche and high LM. 
 
There are limitations to our study. The X chromosome, harboring the androgen receptor gene, 
was not included in the present meta-analysis, which is notable since androgens have a major 
impact on muscle mass. Another potential weakness of this study is our decision to meta-analyze 
body composition results using two different techniques (BIA and DXA). Nevertheless, the two 
methods are highly correlated,
[6]
 and by combining them power to detect GWS loci was greatly 
enhanced. 
In conclusion, we identified one novel LM locus (TNRC6B) and our results suggest that 
genetically-determined increase in LM might exert either harmful or protective effects on 
metabolic traits, depending on its relation to fat mass.  
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Legends to supplemental figures 
 
Figure S1. Quantile-quantile plots of the genome-wide association results of the inverse-
variance weighted meta-analysis.  
Total lean mass according to Model 1 (A; not adjusted for fat masss), Model 2 (B; adjusted for 
fat %)) and Model 3 (C; adjusted for fat mass in kg). 
 
Figure S2. Manhattan plots for the genome-wide meta-analysis results. 
Total lean mass according to Model 1 (A; not adjusted for fat masss), Model 2 (B; adjusted for 
fat %)) and Model 3 (C; adjusted for fat mass in kg). Blue line indicates p = 5 x 10
-8
. Red line 
indicates suggestive genome-wide significant p=2.3 x 10
-6
. 
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Figure S1A
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Figure S1B
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Figure S1C 
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 Figure S2A Figure S2A 
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Figure S2B
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